Could I get the same effect by adding cagrilintide to the semaglutide I already take?

What is sold online under that name is not the trial drug. Cagrilintide is not independently approved, so the only cagrilintide anyone has bought is a grey-market product with no assurance of identity or purity and no legal human-use route. REDEFINE-1 tested a specific co-formulation at 2.4/2.4 mg under trial conditions, which is not what a vial from a website reproduces.

I have type 2 diabetes. Does the 22.7% figure apply to me?

Probably not at that size. REDEFINE-1 excluded type 2 diabetes, and CagriSema was studied separately in people who have it in REDEFINE-2. Weight-loss results are consistently smaller in type 2 diabetes across this whole drug class, so the two trials are read separately rather than merged.

Should I hold off on treatment and wait for CagriSema?

That assumes a date nobody can give you. CagriSema completed phase 3 and was not a general prescription product when this page was researched, and approval status has to be checked against FDA or EMA rather than inferred from a published trial. Whether to start something now or wait is a conversation with a prescriber, who can weigh the delay against your own situation.

CagriSema and Cagrilintide: Where the Data Stands

What this page establishes

REDEFINE-1 randomised 3,417 adults with obesity or overweight plus comorbidity, without T2D, to CagriSema 2.4/2.4 mg, cagrilintide 2.4 mg, semaglutide 2.4 mg or placebo for 68 weeks.
At 68 weeks CagriSema achieved 22.7% weight loss vs 11.8% cagrilintide alone, 16.1% semaglutide alone and 2.3% placebo.
On the treatment-policy estimand the same trial reads 20.4% CagriSema, 11.5% cagrilintide, 14.9% semaglutide, 3% placebo.
40.4% of CagriSema participants lost >=25% of body weight, vs 6.0% cagrilintide, 16.2% semaglutide and 0.9% placebo.

Quick answers

Could I get the same effect by adding cagrilintide to the semaglutide I already take?
What is sold online under that name is not the trial drug. Cagrilintide is not independently approved, so the only cagrilintide anyone has bought is a grey-market product with no assurance of identity or purity and no legal human-use route.
Read the full answer
REDEFINE-1 tested a specific co-formulation at 2.4/2.4 mg under trial conditions, which is not what a vial from a website reproduces.
I have type 2 diabetes. Does the 22.7% figure apply to me?
Probably not at that size. REDEFINE-1 excluded type 2 diabetes, and CagriSema was studied separately in people who have it in REDEFINE-2.
Read the full answer
Weight-loss results are consistently smaller in type 2 diabetes across this whole drug class, so the two trials are read separately rather than merged.
Should I hold off on treatment and wait for CagriSema?
That assumes a date nobody can give you. CagriSema completed phase 3 and was not a general prescription product when this page was researched, and approval status has to be checked against FDA or EMA rather than inferred from a published…
Read the full answer
That assumes a date nobody can give you. CagriSema completed phase 3 and was not a general prescription product when this page was researched, and approval status has to be checked against FDA or EMA rather than inferred from a published trial. Whether to start something now or wait is a conversation with a prescriber, who can weigh the delay against your own situation.

CagriSema produced 22.7% mean weight loss at 68 weeks in REDEFINE-1, beating semaglutide alone and cagrilintide alone in the same trial. It was also reported as a disappointment, because Novo Nordisk had guided toward roughly 25%. Both readings are accurate, which makes this the most useful page in the cluster for understanding how a number becomes a headline. The mechanism is worth attention on its own: amylin is a different pathway from GLP-1, and combining the two is the reason the trial worked.

What amylin does, and how cagrilintide works

Amylin is a hormone co-secreted with insulin from the pancreas. It slows gastric emptying and signals satiety through pathways that are not the GLP-1 pathway. Cagrilintide is a long-acting synthetic analogue of it, given once weekly by injection.

That separation matters. Stacking two drugs that hit the same receptor tends to buy you dose escalation and side effects. Combining two different satiety pathways is a real pharmacological argument for a combination, and REDEFINE-1 was designed to test exactly that by including both monocomponents as comparator arms.

Cagrilintide on its own

The monotherapy arm of REDEFINE-1 reached 11.8% mean weight loss at 68 weeks, or 11.5% on the treatment-policy estimand, against 2.3% to 3% for placebo depending on estimand.

That places cagrilintide alone below semaglutide 2.4 mg, which reached 16.1% in the same trial. As a standalone weight-loss agent it is mid-tier. Its value in this programme is as a combination partner, not as a monotherapy, and it is not independently approved.

REDEFINE-1: the combination against its own parts

REDEFINE-1 randomised 3,417 adults with obesity, or overweight plus a comorbidity, without type 2 diabetes, to one of four arms for 68 weeks. Running both monocomponents as comparators is what makes the result interpretable rather than merely impressive.

The responder numbers move more than the mean The gap in mean loss between CagriSema and semaglutide is 6.6 percentage points. The gap in the proportion of people losing a quarter of their body weight is 40.4% versus 16.2%, which is two and a half times as many. Mean weight loss compresses the tail. Responder thresholds show it.

Arm	Mean weight loss at 68 weeks	Treatment-policy estimand	Lost 25% or more
CagriSema 2.4/2.4 mg	22.7%	20.4%	40.4%
Semaglutide 2.4 mg	16.1%	14.9%	16.2%
Cagrilintide 2.4 mg	11.8%	11.5%	6.0%
Placebo	2.3%	3%	0.9%

The 25% target, and why missing it is not failing

Novo Nordisk had guided the market toward roughly 25% weight loss. REDEFINE-1 delivered 22.7%, and the share price reacted accordingly. Trade coverage framed it as falling short.

That framing is about expectations, not about the drug. Against placebo, against semaglutide alone and against cagrilintide alone, CagriSema won on every comparison the trial was designed to make. It is a framing issue rather than a safety or efficacy one. The lesson generalises: a trial result gets scored against whatever number the market had already priced in, and that number is not part of the science.

The safety picture is the combined gastrointestinal burden of both components, which is what you would expect from stacking an amylin analogue on a GLP-1 agonist.

Results in type 2 diabetes

CagriSema was also studied in adults with overweight or obesity and type 2 diabetes in REDEFINE-2, published in NEJM. Weight-loss results in people with type 2 diabetes are consistently smaller than in people without it across this entire drug class, so the two trials should be read separately rather than merged into one figure.

Regulatory status

CagriSema completed phase 3 with results published in NEJM. It was not a general prescription product at the time this page was researched, and cagrilintide is not independently approved. Status verified 23 August 2026.

Both are sold on the grey market as research chemicals. Those products are not the trial drug, carry no assurance of identity or purity, and have no legal human-use route.

Not medical advice Educational content only, with no dosing or sourcing guidance. Approval status for CagriSema can change, so confirm the current position with FDA or EMA rather than relying on this page. Talk to a prescriber about your own treatment.

The evidence, one row per claim

Claim	Tier	Source
REDEFINE-1 randomised 3,417 adults with obesity or overweight plus comorbidity, without T2D, to CagriSema 2.4/2.4 mg, cagrilintide 2.4 mg, semaglutide 2.4 mg or placebo for 68 weeks.	established	HCPLive
At 68 weeks CagriSema achieved 22.7% weight loss vs 11.8% cagrilintide alone, 16.1% semaglutide alone and 2.3% placebo.	established	Cross-reported; primary is NEJM REDEFINE-1 via Novo Nordisk release
On the treatment-policy estimand the same trial reads 20.4% CagriSema, 11.5% cagrilintide, 14.9% semaglutide, 3% placebo.	established	Applied Clinical Trials
40.4% of CagriSema participants lost >=25% of body weight, vs 6.0% cagrilintide, 16.2% semaglutide and 0.9% placebo.	established	Rheumatology Advisor
The 22.7% result fell short of the roughly 25% figure Novo Nordisk had guided toward, which drove the market reaction.	established	PharmExec
CagriSema was also studied in adults with overweight/obesity and type 2 diabetes (REDEFINE-2, published in NEJM).	established	PubMed

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 6 sourced claims below the fold, each with the document it came from.

Sources consulted: HCPLive, Cross-reported; primary is NEJM REDEFINE-1 via Novo Nordisk release, Applied Clinical Trials, Rheumatology Advisor, PharmExec and 1 more.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

Cagrilintide and CagriSema: The Amylin Route to Weight Loss